Sirona Biochem Corp
- LAST PRICE0.0650
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0550/ 4
- Ask / Lots0.0650/ 118
- Open / Previous Close--- / 0.0650
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Oct 21, 2024
Update: Stonegate Initiates Coverage on Sirona Biochem Corp (TSX-V:SBM), from 2:04PM ET on Monday Oct 21, 2024 by Dow Jones
2:04PM ET on Monday Oct 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sirona Biochem Corp | 17.0M | -6.2x | --- |
Quantum BioPharma Ltd | 12.6M | -0.4x | --- |
BetterLife Pharma Inc | 16.2M | -2.7x | --- |
Biovaxys Technology Corp | 18.3M | -2.5x | --- |
Pharmala Biotech Holdings Inc | 14.6M | -22.2x | --- |
Resverlogix Corp | 15.3M | -1.1x | --- |
Company Information
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.
Contact Information
- Headquarters
- c/o WeWork, 595 Burrard St.VANCOUVER, BC, Canada V7X 1L4
- Phone
- 604-641-4466
- Fax
- 604-608-5471
Executives
- Chairman of the Board, Chief Executive Officer, Founder
- Howard Y
- Chief Financial Officer, Director
- Christopher Hopton
- Chief Scientific Officer, Director
- Geraldine Deliencourt-Godefroy
- Independent Director
- Alex Marazzi
- Independent Director
- Jason Tian
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $17.0M |
|---|---|
Revenue (TTM) | $-16.4K |
Shares Outstanding | 260.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.01 |
EPS | $-0.01 |
Book Value | $-0.01 |
P/E Ratio | -6.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
